POLQ depletion may be used as a novel anticancer strategy potentially superior to PARPis, because it may be effective in tumors with acquired resistance to PARPis, such as HR-deficient cancers of a ‘mutator phenotype’, and also in preventing or attenuating the onset of PARPis resistance in HR deficient naïve cells. This evidence concerns the gene POLQ and cancer.